Oncolin Appoints Member of National Cancer Institute Advisory Board to Its Scientific Advisory Board

June 24, 2008

Oncolin Therapeutics, Inc., (OTCBB:OCOL) is very pleased to announce that Dr. Daniel Von Hoff has joined the company’s Scientific Advisory Board (SAB). Dr. Von Hoff is generally considered to be one of the world’s leading experts in oncology drug development and is an advisor in some capacity to a large number of oncology companies.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX(TM) Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.

Daniel D. Von Hoff, M.D., is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute’s (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. He has done work on the development of many anticancer agents, including paclitaxel, docetaxel, gemcitabine, camptosar and hab-paclitaxel.

“Oncolin Therapeutics is very excited to have someone with Dr Von Hoff’s stature and experience as a member of our SAB. His oncology development experience will be a major addition to our advisory board,” said Dr. Donald Picker, COO of Oncolin.

About Oncolin Therapeutics, Inc.

Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company’s ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin’s future business and financial results, refer to Oncolin’s Quarterly Reports on Form 10-QSB and Annual Report on Form 10-KSB and other reports, which are on file with the Securities and Exchange Commission. Oncolin undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.